Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 409.99M P/E - EPS this Y 60.60% Ern Qtrly Grth -
Income -237.89M Forward P/E 10.85 EPS next Y 105.10% 50D Avg Chg -4.00%
Sales 257.24M PEG 0.10 EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book N/A EPS next 5Y -25.10% 52W High Chg -69.00%
Recommedations 2.00 Quick Ratio 1.14 Shares Outstanding 113.50M 52W Low Chg 21.00%
Insider Own 1.41% ROA -21.75% Shares Float 103.87M Beta 0.51
Inst Own 77.17% ROE - Shares Shorted/Prior 21.53M/25.91M Price 4.34
Gross Margin 38.19% Profit Margin -92.48% Avg. Volume 3,723,385 Target Price 10.43
Oper. Margin -98.78% Earnings Date May 6 Volume 4,840,432 Change -3.34%
About Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc. News
04/24/24 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04/11/24 Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
04/08/24 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
03/16/24 Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
03/15/24 Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
03/14/24 Why Coherus Biosciences Stock Tumbled on Thursday
03/14/24 Q4 2023 Coherus BioSciences Inc Earnings Call
03/13/24 Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
03/13/24 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
03/06/24 In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
03/05/24 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
03/04/24 Coherus Completes Divestiture of Ophthalmology Franchise
02/23/24 Coherus BioSciences Announces New Employment Inducement Grants
02/21/24 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
02/06/24 Why Coherus BioSciences Stock Jumped Today
02/05/24 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
01/25/24 Analysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Be
01/23/24 Why Coherus BioSciences Stock Is Sinking Today
01/22/24 Why Coherus Biosciences Popped Today
01/22/24 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
CHRS Chatroom

User Image neofeudal Posted - 3 hours ago

$CHRS Fair to say this stock has experienced (1) DECLINE and (2) CONSOLIDATION. It is now establishing (3) a BASE and will next experience (4) RECOVERY! Each of these phases has been long and dramatic. So, too, will be the recovery. This is all kinda obvious stuff, but is worth mapping, in case anybody thinks they are not seeing what I’m seeing.

User Image Old_Man_58 Posted - 5 hours ago

$CHRS All I could find so far,no abstract yet. https://meetings.asco.org/abstracts-presentations/233962

User Image neofeudal Posted - 6 hours ago

$CHRS All 14 had a dna condition called mismatch repair deficiency. So I take it that the response is not the same otherwise. CHS114 (I think) discovered a similar genetic marker that showed it would perform particularly well, and P2 is going to have an arm focusing on those patients. So, similar news is possible for chrs in the months ahead.

User Image IBott Posted - 16 hours ago

$CHRS SHAREHOLDER VOTE Voted against all recommendations this am as a protest.

User Image Samishere Posted - 1 day ago

$CHRS Blah blah blah , bloviating blah , Show me the money ! Now, not next quarter , next year , 2028. Now! All the pumping does not change the fact that this garbage is $2 a share , soon to be a buck fifty. There’s a reason , and you pumps just can’t seem to grasp it ! But hey , great buying opportunity at 1.50 coming very soon 👍🏼 I’ll refrain from name calling as the proof is in the pudding , or in this case the SP !

User Image PolishPowerSki Posted - 1 day ago

$CHRS SamiDe🤡, the difference between you and anyone to be taken seriously is that you won't acknowledge that there are very real short- and long-term revenue sources that place CHRS' FMV much higher than $230M. Udenyca alone is worth its market cap. That is undeniable, full stop. Then, add Tori, Yusimry (and its positive drivers in 2025) and its pipeline (and there is considerable value there), you have $1B FMV. Not a pump, just a fact. Irrationally driven by shorts only persists for a finite period. How lomg? That's the only real question. You know this true, but you"re too much an intellectual fraud to admit it.

User Image FOUNDRY123 Posted - 1 day ago

$CHRS If we can get some guidance this report that is within expectations please. Floundering on lack of guidance. If they say something along the lines of ”expect profitability in X quarter 2024” sucker is going to fly!!

User Image Samishere Posted - 1 day ago

$CHRS And another none CHRS pump! Old video , nothing about CHRS Means literally zero! Zero as in the same amount of revenue CHRS sees from any of your pumps! It’s why you have a $2 stock price moron ! If any of this had anything to do with CHRS it would be 2 bucks , soon to be a buck fifty a share ! 🤡🤡🤡🤡🤡

User Image Samishere Posted - 1 day ago

$CHRS AGAIN! What does this have to do with CHRS? Old news , NOT CHRS and why you push this nonsense is beyond me

User Image Fomoninja Posted - 1 day ago

$CHRS It's not too late to switch sides Samithe🤡inhere. Attached news for you! Milestones are coming, I can smell it!💎💎🚀🚀🚀🚀🚀🚀🚀🚀🚀🌛🌛🪐🪐https://youtu.be/a0rbO3pnqDI?si=VicwuuAGpTCTOaHE

User Image Fomoninja Posted - 1 day ago

$CHRS Wow you lie non stop shorty! Being studied with a drug that was all over the news.💎💎👐👐🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🌛🌛🪐🪐

User Image Samishere Posted - 1 day ago

$CHRS That was a deal with SRF from 2020! GSK isn’t even working on that anymore ! There is NO payment of any kind due CHRS ! You’re the one making up complete nonsense!

User Image Fomoninja Posted - 1 day ago

$CHRS You have destroyed nothing. GSK milestones and royalties still on the table. Quit making shit up. 💎💎👐👐🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🌛🌛🪐🪐

User Image Samishere Posted - 1 day ago

$CHRS One pumper destroyed ,, about 5 more to go! Owed $500 million, LOL!!! What a 🤡 show this entire thing has become !!

User Image Samishere Posted - 1 day ago

$CHRS Sanity from PolishPumoer , how refreshing! Ninja’s inane pump sorted , now how about you tackle the king misinformation spreaders tonee & neofraud? Owed $500 million!!! LMFAO!!!!!

User Image agamemnus Posted - 1 day ago

$CHRS Another 45m and I can take this off my watchlist. 🙏

User Image MoneyTree82 Posted - 1 day ago

$CHRS did you all see how much $ABBV has gone down in the last few days. Article said sales for Humira dropped 32% this quarter that value represents billions of dollars hopefully $CHRS was able to capture some of that market share! Because billions is a small percentage for $ABBV but windfall for $CHRS! $XBI

User Image MoneyTree82 Posted - 1 day ago

$CHRS 16 minutes and we had a Green Day green candle! 💪 very needed! Keep the trend going next week! $XBI

User Image Tonee1234 Posted - 1 day ago

$CHRS

User Image MoneyTree82 Posted - 1 day ago

$CHRS can we trade over a million shares by the closing bell? $XBI

User Image MoneyTree82 Posted - 1 day ago

$CHRS only 113 million shares! Not much!

User Image Samishere Posted - 1 day ago

$CHRS 🤪

User Image MoneyTree82 Posted - 1 day ago

$CHRS can we please get a flood of buy side volume in the last hour! $XBI

User Image MoneyTree82 Posted - 1 day ago

$CHRS buy side volume! 2 million shares per day dropped all the way to under a million per day! Come on Denny stand by your company and personally buy some share with the large paycheck the company pays you.

User Image Tonee1234 Posted - 1 day ago

$CHRS FINALLY SOMEONE UNDERSTANDS MY MORE "EMOTIONAL" SIDE --- WHEN I'M NOT HORN DOGGING MY WAY THROUG THE NUMBERS NOT THAT I EVER HAD ANY DOUBT

User Image Microcap777 Posted - 1 day ago

$CHRS Sure would be nice to bust through $2.10 and close the day there. There have been a couple recent Fridays for whatever reason where we have seen that type of movement, so let's have another one.

User Image neofeudal Posted - 1 day ago

$CHRS The way you feel on an up day is how you should feel on a down day...in terms of buying. This ticker is on sale all the way to double digits.

User Image LetchurWinnersRun Posted - 1 day ago

$CHRS Added another 500 yesterday at 1.95. Easy average down.

User Image calibran_de Posted - 1 day ago

$CHRS good news and skyrocket, please

User Image ZenInvestorZR Posted - 1 day ago

$CHRS Added here 6k shares

Analyst Ratings
HC Wainwright & Co. Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 14, 24
Baird Outperform Jan 23, 24
Truist Securities Buy Jan 23, 24
HC Wainwright & Co. Buy Dec 27, 23
HC Wainwright & Co. Buy Dec 7, 23
Truist Securities Buy Nov 28, 23
Baird Outperform Nov 17, 23
Maxim Group Hold Nov 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wahlstrom Mats Director Director Feb 01 Option 1.67 59,988 100,180 99,988 02/05/24
Lanfear Dennis M President & CEO President & CEO Nov 22 Sell 2.02 223,100 450,662 731,693 11/24/23
Lanfear Dennis M President & CEO President & CEO Nov 22 Option 1.42 299,940 425,915 954,793 11/24/23
Vexler Vladimir Chief Scientific Off.. Chief Scientific Officer Mar 11 Option 7.14 102,480 731,707 167,626 03/11/21
Vexler Vladimir Chief Scientific Off.. Chief Scientific Officer Mar 11 Sell 16.25 114,240 1,856,400 53,386 03/11/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Mar 09 Option 9.3 20,312 188,902 80,051 03/09/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Mar 09 Sell 15.46 26,649 411,994 53,402 03/09/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Feb 03 Option 10.05 7,402 74,390 68,697 02/03/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Feb 03 Sell 21.55 7,402 159,513 61,295 02/03/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Jan 27 Option 10.05 40,000 402,000 107,439 01/27/21
Viret Jean-Frederic Chief Financial Offi.. Chief Financial Officer Jan 27 Sell 19.55 46,144 902,115 61,295 01/27/21
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Dec 09 Option 12.54 8,791 110,239 41,360 12/09/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Dec 09 Sell 18.42 8,791 161,930 32,569 12/09/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Nov 19 Option 7.6 6,783 51,551 36,852 11/19/20
Anicetti Vincent R Chief Operating Offi.. Chief Operating Officer Nov 19 Sell 17.71 22,770 403,257 32,569 11/19/20